Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT06908616Recruiting
Study of Low White Blood Cell Counts and Blood Types in Newborns
This trial looks at how common a harmless condition called ethnic neutropenia (low white blood cells) and a specific blood type (Duffy null) are in newborns at Kaplan Medical Center. It helps doctors understand normal blood cell differences across ethnic groups.
Rehovot, IsraelAges 1 minute–1 day - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07220187RecruitingPhase 3
Adding pirtobrutinib to usual treatment for newly diagnosed Richter transformation
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Irvine, CaliforniaAges 18 years+ - NCT05846880RecruitingEarly Phase 1
Vitamin D3 supplement for people with multiple myeloma
This early-phase study tests whether taking a Vitamin D3 supplement can be safe and helpful for people with symptomatic multiple myeloma. It may help researchers understand how Vitamin D affects the disease and how patients tolerate treatment.
Augusta, GeorgiaAges 18 years+ - NCT07214324Recruiting
Predicting blood cancer progression with genetic analysis
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
BolognaAges 18 years+ - NCT05702502Recruiting
Testing a DNA marker in lymphoma-related HLH
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
Nottingham, NottinghamshireAges 18 years+ - NCT06156579RecruitingPhase 2
Venetoclax and Decitabine for Relapsed or Refractory AML
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07216443RecruitingPhase 2
Study of orca-t for leukemia or MDS with reduced intensity chemo
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
Los Angeles, CaliforniaAges 18 years+ - NCT07214753Recruiting
Benralizumab for severe eosinophilic asthma in Italy
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
Salerno, BattipagliaAges 18 years+ - NCT07215585RecruitingPhase 3
New targeted therapy for elderly or unfit lymphoma patients
This trial tests a new targeted therapy (AZD0486) as a first treatment for older or less fit people with large B-cell lymphoma. It is for those who cannot tolerate the usual strong chemo, aiming to be gentler while still fighting the cancer.
ClaytonAges 65–130 - NCT07218341RecruitingPhase 4
Continuing pirtobrutinib for CLL or SLL patients
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Mobile, AlabamaAges 18 years+ - NCT07218185Enrolling by invitation
Fibrinogen treatment for severe bleeding after trauma
This study tests an investigational treatment called INTERCEPT Fibrinogen Complex (IFC) for people with severe bleeding after a traumatic injury. The treatment helps restore a key blood-clotting protein to try to stop the bleeding and improve survival.
Aurora, ColoradoAges 18 years+ - NCT07215975Recruiting
Luspatercept for adults with transfusion-dependent beta-thalassemia
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
Al JahraAges 18 years+ - NCT07220915RecruitingPhase 3
Study of Panzyga to prevent infections in people with weak immune systems
This trial tests if a medication called Panzyga can help prevent infections in people with autoimmune conditions who have low antibody levels after B-cell therapy. It may be an option if you have a condition like multiple sclerosis, rheumatoid arthritis, or lupus.
Glendale, ArizonaAges 18 years+ - NCT07220564RecruitingPhase 1
Study of a new medicine for haemophilia A
This study tests a new medicine called Inno8 in people with haemophilia A. It looks at how different doses work in the body and may help improve treatment options.
Aurora, ColoradoAges 18–64 - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT06913998Recruiting
NUDT15 gene study for Taiwanese IBD patients
This study looks at how certain gene changes (NUDT15) affect people with inflammatory bowel disease (IBD) in Taiwan. It aims to help doctors better understand and treat IBD.
TaipeiAges 1–25 - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
Bakersfield, CaliforniaAges 12 years+ - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
Duarte, CaliforniaAges 18 years+ - NCT03802773Recruiting
Cord blood transplant with strong chemo to prevent relapse
This trial tests a cord blood transplant using strong (myeloablative) chemotherapy to prepare your body, plus post-transplant treatment to reduce graft-versus-host disease (GVHD). It may help certain blood cancers when other transplant options are limited.
Roma, RMAges 18–75 - NCT04517656Recruiting
Testing blood markers after a bone marrow donor transplant
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Saint-EtienneAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.